Identification of copy number alterations as targets for available drugs involved in T-ALL leukemogenesis and prognosis
- Research Leader:
- Dra. Eulàlia Genescà
- Josep Carreras Leukaemia Research Institute (IJC). ALL research group
Acute Lymphoblastic Leukemia is still a non-curable neoplasia mainly in adult patients. The survival rates for ALL are much lower in adults than in children. The reasons for this survival difference lie largely in the higher frequency of poor prognosis subtypes of ALL in adults and a poorer tolerance of the treatment as age increases. Except for selected subgroups (i.e., Ph+ ALL), the current therapeutic protocols for ALL do not take into account the differences in the molecular background of the disease, and few new alternative therapies are only available in refractory or resistant ALL.
Contact person Dra. Eulàlia Genescà
Web link www.carrerasresearch.org